Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation CarriersIngrid A.W. van Rijsingen, Yigal M. Pinto, Eloisa Arbustini et al.|Journal of the American College of Cardiology|2012Cited by 519
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trialMaarten Groenink, B. J. M. Mulder, Alexander W. den Hartog et al.|European Heart Journal|2013Cited by 396
Outcome in Phospholamban R14del CarriersIngrid A.W. van Rijsingen, Arthur A.M. Wilde, Paul A. van der Zwaag et al.|Circulation Cardiovascular Genetics|2014Cited by 190
Beneficial Outcome of Losartan Therapy Depends on Type of <i>FBN1</i> Mutation in Marfan SyndromeRomy Franken, Gerard Pals, Alexander W. den Hartog et al.|Circulation Cardiovascular Genetics|2015Cited by 165
The Risk for Type B Aortic Dissection in Marfan SyndromeAlexander W. den Hartog, Maarten Groenink, Romy Franken et al.|Journal of the American College of Cardiology|2015Cited by 153